This week in drug discovery (24-28 June) 

News round-up for 24-28 June by DDW Senior Digital Content Editor Diana Spencer.

This week has seen some exciting advances in neuroscience drug discovery, including Phase II clinical trials for two potentially game-changing treatments, a synapse-regenerating drug for Alzheimer’s and a gene therapy for Parkinson’s, as well as the launch of DDW’s latest In Focus report.

The top stories:

Clinical trial to repurpose HIV drugs to treat brain tumours

Drugs developed to treat HIV and AIDS are being trialled for the first time in patients with multiple brain tumours.

Drugs for enlarged prostate could prevent neurodegeneration

A new study suggests that certain drugs commonly used to treat enlarged prostate may also decrease the risk for dementia with Lewy bodies (DLB) and potentially other neurodegenerative diseases.

Synapse-regenerating drug could reverse decline in Alzheimer’s

Spinogenix has initiated a Phase II trial to evaluate SPG302 for the treatment of adult participants with mild-to-moderate Alzheimer’s disease (AD), following approval for the trail in Australia.

Gene therapy for Parkinson’s disease progresses to Phase II

A new Phase II trial, REGENERATE-PD, will study AB-1005, an adeno-associated virus 2 (AAV2) glial cell line-derived neurotrophic factor (GDNF) gene therapy for the treatment of moderate-stage Parkinson’s disease.

New eReport: Advances in neuroscience research

The global prevalence of dementia is approximately 24 million, and is predicted to double every 20 years until at least 2040.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free